The Worldwide Next-generation Antibodies Market Will Generate $11.6 Bn in 2020

Thursday 2 June 2016, Amsterdam

Market Research Report Press Release A new report, now available on ASDReports, published in April 2016, forecasts that the worldwide next-generation antibodies market will generate $11.6 billion in 2020. That revenue forecast and others appear in Next-Generation Antibody Therapies Market Forecast 2016-2026: Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents.

Arshad Ahad, a senior pharmaceutical industry analyst, said:

“Next-generation antibody therapies are treatments based on antibodies that have been engineered or otherwise designed to have advantages over simple monoclonal antibodies. Next-generation antibodies are establishing themselves in the market, seven years after the current crop of novel therapies first reached the market with the approval of Kalbitor and Removab in 2009.

“Sales of Adcetris and Kadcyla constitute the majority of revenues in the market in 2016, but over the next ten years rapid growth will stem from the launch of biosimilar drugs, and later from new engineered and bispecific antibody therapies. A strong and varied R&D pipeline will propel this market to new heights from 2016 to 2026.”
Next-Generation Antibody Therapies Market Forecast 2016-2026

Next-Generation Antibody Therapies Market Forecast 2016-2026

Publish date : April 2016
Report code : ASDR-275433
Pages : 241

Global Next-Generation Antibody Therapies Market Forecast 2018-2028

Global Next-Generation Antibody Therapies Market Forecast 2018-2028

Publish date : September 2018
Report code : ASDR-468859
Pages : September 2018

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News